TetraScience | September 03, 2021
TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design.
"In order to take advantage of innovative data science applications including AI/ML, it's important to start with harmonizing R&D data in the cloud," stated Chad Garrett, TetraScience CRO, "We're excited to partner with Zymeworks on their data cloud initiative and help them deliver on their mission to enable patients to return home to their loved ones, disease free."
The initial Zymeworks deployment of Tetra Data Platform is in production and integrated with key systems and instruments supporting critical lab workflows. By automating and standardizing the flow of data across all sources and targets, the Tetra R&D Data Cloud will deliver faster and richer insights for Zymeworks' scientists. Additionally, Zymeworks will benefit from cloud-native architecture with greater uptime, security, redundancy, governance, and archival capabilities.
TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D.
GATC Health Corp | April 22, 2022
GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform.
Prodrugs are physiologically inactive chemicals that are converted to drugs in the body. Aspirin, Plavix, and Prednisone are just a few examples. The novel new prodrug developed by GATC Health is meant to trigger programmed cell death in malignant cancer tissues and could be used to treat glioblastoma brain tumors.
Due to the difficulty of delivering and selecting drug-target interactions, this unique technique of treatment has not been conceivable before, but it has the potential to improve safety and selectivity. Furthermore, this new prodrug formulation has the potential to significantly lessen the collateral harm produced by past iterations of chemical agents employed to treat cancer. This style, according to the business, will lead to many more advances in innovative cancer therapies.
I am very excited that we are continuing to expand our portfolio at GATC Health and entering in oncology with this innovative platform to meet unmet needs of cancer patients, Glioblastoma accounts for half of all the cancerous brain tumors in adults. We see about 12 to 18 months average survival time for these patients with only 5% of patients surviving more than five years, highlighting the unmet need for innovation for these patients. Our new prodrug has the potential to differentiate between glioblastoma cells and healthy neuron growth, preventing replication of cancer cells for glioblastoma. This new technology may also be used for other tumors. Global spending on therapeutics and supportive care of cancer is continuing to grow and be is expected to reach $200 billion in 2022. With growing incidence of cancer in patients, oncology is the focus area for the 10 largest pharma companies, and we are looking forward to partnering with them to bring glioblastoma patients and other cancer patients a safe, effective cure."
Preetaman Wadhwa, the company's Chief Marketing Officer.
Pfizer, BioNTech | May 10, 2021
Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescription Drug User Fee Act (PDUFA).
The Pfizer-BioNTech COVID-19 Vaccine is now available in the United States under an Emergency Use Authorization (EUA) issued by the Food and Drug Administration (FDA) on December 11, 2020. Since then, the firms have distributed more than 170 million doses of the vaccine in the United States. The next step in the comprehensive FDA evaluation process is the submission of a BLA, which includes longer-term follow-up data for acceptance and approval.
Pfizer and BioNTech started the BLA process by providing the nonclinical and clinical data needed to justify the licensure of the COVID-19 vaccine for use in people aged 16 and up. This covers the most recent analyses from the pivotal Phase 3 clinical trial, in which the vaccine's effectiveness and safety profile were detected up to six months after the second dose. In the coming weeks, the companies will submit the required manufacturing and facility details for licensure, completing the BLA.
Pfizer and BioNTech have since submitted to expand the new EUA for their COVID-19 vaccine to cover individuals aged 12 to 15. The firms plan to send a supplemental BLA to facilitate vaccine licensure in this age group until the requisite data is available six months after the second vaccine dose.
BioNTech and Pfizer collaborated to create the Pfizer-BioNTech COVID-19 Vaccine, which is built on BioNTech's patented mRNA technology. BioNTech is the European Union's Marketing License Holder, as well as the holder of emergency use authorizations or similar in the United States (along with Pfizer), the United Kingdom, Canada, and other countries in advance of a planned application for full marketing authorizations in these countries.
The Pfizer-BioNTech COVID-19 Vaccine has not been authorized or licensed by the United States Food and Drug Administration (FDA), but it has been authorized for emergency use by the FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in people aged 16 and up. The emergency use of this product is only permitted for the duration of the declaration the circumstances justify the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act until the declaration is terminated or the authorization is revoked sooner.
At Pfizer, they utilize science and its global resources to deliver treatments to patients that significantly extend and change their lives. In the discovery, development, and manufacture of health care products, including innovative medicines and vaccines, they aim to set the benchmark for consistency, safety, and value. Every day, Pfizer colleagues collaborate in developing and emerging markets to advance wellness, prevention, treatments, and remedies for today's most feared diseases. As one of the world's leading innovative biopharmaceutical firms, they partner with health care providers, governments, and local communities to promote and improve access to reliable and affordable health care around the world.
Biopharmaceutical New Technologies is a next-generation immunotherapy firm that is developing novel cancer and other severe disease therapies. For the accelerated production of new biopharmaceuticals, the company makes use of a diverse set of computational discovery and therapeutic drug platforms. Its oncology product candidates include individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies, and small molecules from Fosun Pharma and Pfizer.